IN8bio (INAB) 10-Q 10 Sep 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Sep. 07, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Registrant Name	IN8BIO, INC.
Entity Central Index Key	0001740279
Entity Tax Identification Number	82-5462585
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	No
Entity Filer Category	Non-accelerated Filer
Entity File Number	001-39692
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	79 Madison Avenue
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10016
City Area Code	646
Local Phone Number	600-6438
Trading Symbol	INAB
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		18,754,553
Document Quarterly Report	true
Document Transition Report	false

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash	$ 11,999	$ 17,994
Prepaid expenses and other current assets	168	150
Total Current Assets	12,167	18,144
Non-current assets
Property and equipment, net	142	186
Deferred offering costs	3,362	2,439
Right of use assets - financing leases	990	0
Right of use assets - operating leases	762	0
Other non-current assets	141	141
Total Non-Current Assets	5,397	2,766
Total Assets	17,564	20,910
Current liabilities
Accounts payable	462	620
Accrued expenses and other current liabilities	1,485	1,778
Short-term financing lease liability	517	0
Short-term operating lease liability	135	0
Loan payable, current	174	174
Total Current Liabilities	2,773	2,572
Deferred rent	0	17
Long-term financing lease liability	432	0
Long-term operating lease liability	698	0
Total Liabilities	3,903	2,589
Commitments and Contingencies
Convertible preferred stock, Series A, par value $0.0001 per share; 27,564,260 shares authorized at June 30, 2021 and December 31, 2020; 9,993,727 shares, issued and outstanding at June 30, 2021 and December 31, 2020, and a liquidation preference of $39,390 and $37,969 at June 30, 2021 and December 31, 2020, respectively	34,900	34,900
Stockholders' Deficit
Common stock, par value $0.0001 per share; 50,700,000 shares authorized at June 30, 2021 and December 31, 2020; 3,764,488 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	1	1
Additional paid-in capital	2,211	1,458
Accumulated deficit	(23,451)	(18,038)
Total Stockholders' Deficit	(21,239)	(16,579)
Total Liabilities, Convertible Preferred Stock and Stockholders' Deficit	$ 17,564	$ 20,910

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Convertible preferred stock, Series A, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, Series A, shares authorized	27,564,260	27,564,260
Convertible preferred stock, Series A, shares issued	9,993,727	9,993,727
Convertible preferred stock, Series A, shares outstanding	9,993,727	9,993,727
Convertible preferred stock, Series A, liquidation preference, value	$ 39,390	$ 37,969
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,700,000	50,700,000
Common stock, shares, issued	3,764,488	3,764,488
Common stock, shares, outstanding	3,764,488	3,764,488

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating expenses:
Research and development	$ 2,064	$ 1,784	$ 3,310	$ 2,836
General and administrative	986	1,090	2,103	1,729
Total operating expenses	3,050	2,874	5,413	4,565
Loss from operations	(3,050)	(2,874)	(5,413)	(4,565)
Net loss	(3,050)	(2,874)	(5,413)	(4,565)
Net loss attributable to common stockholders (Note 11)	$ (3,765)	$ (3,178)	$ (6,834)	$ (5,129)
Net loss per share attributable to common stockholders – basic and diluted	$ (1)	$ (0.92)	$ (1.82)	$ (1.52)
Weighted-average number of shares used in computing net loss per common share, basic and diluted	3,764,488	3,462,182	3,764,488	3,383,774

Condensed Statements of Convert

Condensed Statements of Convertible Preferred Stock, Common Stock and Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member]License Agreement [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Temporary equity shares beginning at Dec. 31, 2019		2,713,980
Temporary equity amount beginning at Dec. 31, 2019		$ 8,896
Shares beginning at Dec. 31, 2019			3,235,671
Balance beginning at Dec. 31, 2019	$ (9,242)		$ 1		$ 238	$ (9,481)
Stock issued during period shares new issues, amount	200	$ 5,480			200
Stock issued during period shares new issues, shares		1,533,947	182,500	44,011
Stock-based compensation expense	18				18
Net loss	(1,691)					(1,691)
Temporary equity shares ending at Mar. 31, 2020		4,247,927
Temporary equity amount ending at Mar. 31, 2020		$ 14,376
Shares ending at Mar. 31, 2020			3,462,182
Balance ending at Mar. 31, 2020	(10,715)		$ 1		456	(11,172)
Temporary equity shares beginning at Dec. 31, 2019		2,713,980
Temporary equity amount beginning at Dec. 31, 2019		$ 8,896
Shares beginning at Dec. 31, 2019			3,235,671
Balance beginning at Dec. 31, 2019	(9,242)		$ 1		238	(9,481)
Stock-based compensation expense	38
Net loss	(4,565)
Temporary equity shares ending at Jun. 30, 2020		4,247,927
Temporary equity amount ending at Jun. 30, 2020		$ 14,376
Shares ending at Jun. 30, 2020			3,462,182
Balance ending at Jun. 30, 2020	(13,569)		$ 1		476	(14,046)
Temporary equity shares beginning at Mar. 31, 2020		4,247,927
Temporary equity amount beginning at Mar. 31, 2020		$ 14,376
Shares beginning at Mar. 31, 2020			3,462,182
Balance beginning at Mar. 31, 2020	(10,715)		$ 1		456	(11,172)
Stock-based compensation expense	20				20
Net loss	(2,874)					(2,874)
Temporary equity shares ending at Jun. 30, 2020		4,247,927
Temporary equity amount ending at Jun. 30, 2020		$ 14,376
Shares ending at Jun. 30, 2020			3,462,182
Balance ending at Jun. 30, 2020	$ (13,569)		$ 1		476	(14,046)
Temporary equity shares beginning at Dec. 31, 2020	9,993,727	9,993,727
Temporary equity amount beginning at Dec. 31, 2020	$ 34,900	$ 34,900
Shares beginning at Dec. 31, 2020			3,764,488
Balance beginning at Dec. 31, 2020	(16,579)		$ 1		1,458	(18,038)
Stock-based compensation expense	361				361
Net loss	(2,363)					(2,363)
Temporary equity shares ending at Mar. 31, 2021		9,993,727
Temporary equity amount ending at Mar. 31, 2021		$ 34,900
Shares ending at Mar. 31, 2021			3,764,488
Balance ending at Mar. 31, 2021	$ (18,581)		$ 1		1,819	(20,401)
Temporary equity shares beginning at Dec. 31, 2020	9,993,727	9,993,727
Temporary equity amount beginning at Dec. 31, 2020	$ 34,900	$ 34,900
Shares beginning at Dec. 31, 2020			3,764,488
Balance beginning at Dec. 31, 2020	(16,579)		$ 1		1,458	(18,038)
Stock-based compensation expense	753
Net loss	$ (5,413)
Temporary equity shares ending at Jun. 30, 2021	9,993,727	9,993,727
Temporary equity amount ending at Jun. 30, 2021	$ 34,900	$ 34,900
Shares ending at Jun. 30, 2021			3,764,488
Balance ending at Jun. 30, 2021	(21,239)		$ 1		2,211	(23,451)
Temporary equity shares beginning at Mar. 31, 2021		9,993,727
Temporary equity amount beginning at Mar. 31, 2021		$ 34,900
Shares beginning at Mar. 31, 2021			3,764,488
Balance beginning at Mar. 31, 2021	(18,581)		$ 1		1,819	(20,401)
Stock-based compensation expense	392				392
Net loss	$ (3,050)					(3,050)
Temporary equity shares ending at Jun. 30, 2021	9,993,727	9,993,727
Temporary equity amount ending at Jun. 30, 2021	$ 34,900	$ 34,900
Shares ending at Jun. 30, 2021			3,764,488
Balance ending at Jun. 30, 2021	$ (21,239)		$ 1		$ 2,211	$ (23,451)

Condensed Statements of Conve_2

Condensed Statements of Convertible Preferred Stock, Common Stock and Stockholders' Deficit (Unaudited) (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Convertible Preferred Stock [Member]
Payments of stock issuance costs	$ 16

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Operating activities
Net loss	$ (5,413,000)	$ (4,565,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	44,000	44,000
Non-cash stock-based compensation	753,000	38,000
Amortization of financing lease right-of-use assets	250,000	0
Amortization of operating lease right-of-use assets	61,000	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(62,000)	8,000
Other non-current assets	0	(1,000)
Accounts payable	(372,000)	1,000
Accrued expenses and other current liabilities	(221,000)	1,191,000
Short-term operating lease liabilities	62,000	0
Long-term operating lease liabilities	(70,000)	0
Net cash used in operating activities	(4,968,000)	(3,284,000)
Financing activities
Proceeds from the issuance of common stock - Class A	0	200,000
Proceeds from issuance of preferred stock - Series A, net of $16 of issuance costs	0	5,480,000
Principal payments on financing leases	(248,000)	0
Proceeds from issuance of loan	0	174,000
Deferred offering costs paid	(779,000)	0
Net cash (used in) provided by financing activities	(1,027,000)	5,854,000
Net (decrease) increase in cash and restricted cash	(5,995,000)	2,570,000
Cash and restricted cash at beginning of period	17,994,000	610,000
Cash and restricted cash at end of period	11,999,000	3,180,000
Supplemental disclosure of non-cash financing and investing information:
Deferred offering costs included in accounts payable and accrued expenses	1,020,000	0
Initial measurement of operating lease right-of-use assets and liabilities	$ 3,483,000	$ 0

Condensed Statements of Cash _2

Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Series A Preferred Stock
Payments of stock issuance costs	$ 16	$ 16

Organization and Nature of Oper

Organization and Nature of Operations	6 Months Ended
	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Nature of Operations	1. ORGANIZATION AND NATURE OF OPERATIONS Organization and Business IN8bio, Inc. (the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. The Company’s lead product candidates are currently in Phase 1 clinical trials: INB-200, for the treatment of newly diagnosed glioblastoma (“GBM”), and INB-100, for the treatment of patients with leukemia that are undergoing hematopoietic stem cell transplantation (“HSCT”). In addition, the Company’s DeltEx platform has yielded a broad portfolio of preclinical programs, including INB-400 and INB-300, focused on addressing other solid tumor types. Incysus, Inc. (“Incysus”) was a corporation formed in the State of Delaware on November 23, 2015 and Incysus, Ltd. was incorporated in Bermuda on February 8, 2016. Incysus was the wholly owned United States subsidiary of Incysus, Ltd. On May 7, 2018, Incysus, Ltd. reincorporated in the United States in a domestication transaction (the “Domestication”) in which Incysus, Ltd. converted into a newly formed Delaware corporation, Incysus Therapeutics, Inc. (“Incysus Therapeutics”). On July 24, 2019, Incysus Therapeutics merged with Incysus. Incysus Therapeutics subsequently changed its name to IN8bio, Inc. in August 2020. Following the Domestication in May 2018 and the merging of Incysus Therapeutics and Incysus in July 2019, the Company did not have any subsidiaries to consolidate as of December 31, 2020. The Company is headquartered in New York, New York. Coronavirus pandemic Th e current COVID-19 (coronavirus) pandemic, which is impacting worldwide economic activity, poses risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to shutdowns that may be requested or mandated by governmental authorities. The extent to which the coronavirus impacts the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. COVID-19 may impact the timing of regulatory approval of the investigational new drug (INDs) for clinical trials, the enrollment of any clinical trials that are approved, the availability of clinical trial materials and regulatory approval and commercialization of our products. COVID-19 may also impact the Company’s ability to access capital, which could negatively impact short-term and long-term liquidity. Liquidity and Capital Resources Through June 30, 2021, the Company funded its operations primarily with proceeds from the initial closing and additional closings of its Series A convertible preferred stock financing (“Series A Financing”). The Company has incurred recurring losses and negative operating cash flows from operations since its inception, including net losses of $ 5.4 million and $ 4.6 million for the six months ended June 30, 2021 and 2020, respectively. As of June 30, 2021, the Company had an accumulated deficit of $ 23.5 million. The Company expects to continue to generate operating losses for the foreseeable future. On August 3, 2021 , the Company completed its initial public offering (“IPO”) in which it issued and sold 4,000,000 shares of its common stock at a public offering price of $ 10.00 per share pursuant to its Registration Statement on Form S-1, as amended (File No. 333-249530). The Company received net proceeds from the initial public offering of $ 32.6 million, after deducting underwriters’ discounts, commissions, and estimated offering-related costs of $ 7.4 million. B. Riley Securities Inc. acted as the sole book-running manager for the IPO. The Company has not yet generated product sales and as a result has experienced operating losses since inception. The Company expects to incur additional losses in the future to conduct research and development and will need to raise additional capital to fully implement management’s business plan. The Company intends to raise such capital through the issuance of additional equity, and potentially through borrowings, strategic alliances with partner companies and other licensing transactions. However, if such financing is not available at adequate levels, the Company may need to reevaluate its operating plans. Management believes that its existing cash of $ 12.0 million as of June 30, 2021 and the net proceeds of $ 32.6 million from the IPO will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance of these condensed financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Company has prepared the accompanying condensed financial statements in conformity with generally accepted accounting principles in the United States (“US GAAP”). Un audited Interim Financial Information The condensed financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these condensed financial statements, as is permitted by such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements and notes thereto for the years ended December 31, 2020 and 2019 included in the Company’s final prospectus that forms part of the Company’s Registration Statement on Form S-1 (File No. 333-249530), filed with the SEC pursuant to Rule 424(b)(4) on July 30, 2021 (the “Prospectus”). The results for any interim period are not necessarily indicative of results for any future period. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included Use of Estimates The preparation of condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses during the reporting periods presented. Such estimates and assumptions are used for, but are not limited to, the accrual of research and development expenses, deferred tax assets and liabilities and related valuation allowance, fair value of common stock and stock-based compensation, and the useful lives of property and equipment. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Leases Effective January 1, 2021, the Company adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASU 2016-02” or “ASC 842”), using the modified retrospective method and utilized the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under Accounting Standards Codification ("ASC") ASC 840, Leases . At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company elected the following practical expedients, which must be elected as a package and applied consistently to all of its leases at the transition date (including those for which the entity is a lessee or a lessor): i) the Company did not reassess whether any expired or existing contracts are or contain leases; ii) the Company did not reassess the lease classification for any expired or existing leases (that is, all existing leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases, and all existing leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases); and iii) the Company did not reassess initial direct costs for any existing leases. For leases that existed prior to the date of initial application of ASC 842 (which were previously classified as operating leases), a lessee may elect to use either the total lease term measured at lease inception under ASC 840 or the remaining lease term as of the date of initial application of ASC 842 in determining the period for which to measure its incremental borrowing rate. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. On the adoption date, $ 1.7 million was recognized as total lease liabilities and $ 1.8 million was recognized as total right-of-use assets on the Company’s condensed balance sheet. Deferred Offering Costs The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process preferred stock or common stock financings as deferred offering costs until such financings are consummated. The deferred offering costs will be offset against the IPO proceeds during the quarter ending September 30, 2021 as a result of the consummation of the IPO. As of June 30, 2021 and December 31, 2020, the Company had deferred offering costs related to the IPO of $ 3.4 million and $ 2.4 million, respectively. Recently Issued Accounting Standards Updates In December 2019, the Financial Accounting Standards Board ("FASB") issued ASU) No. 2019-12, Simplifying the Accounting for Income Taxes . ASU No. 2019-12 eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. This update is effective for entities other than public business entities, including emerging growth companies that elected to defer compliance with new or revised financial accounting standards until a company that is not an issuer is required to comply with such standards, for annual reporting periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on the condensed financial statements.

Property And Equipment, Net

Property And Equipment, Net	6 Months Ended
	Jun. 30, 2021
Property Plant And Equipment [Abstract]
Property and Equipment, Net	3. PROPERTY AND EQUIPMENT, NET Property and equipment, net consist of the following (in thousands): June 30, December 31, Machinery and equipment $ 443 $ 443 Less accumulated depreciation ( 301 ) ( 257 ) Property and equipment, net $ 142 $ 186 Depreciation expense was $ 22,000 for the three months ended June 30, 2021 and 2020 and was $ 44,000 for the six months ended June 30, 2021 and 2020.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2021
Payables And Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	4. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consist of the following (in thousands): June 31, December 31, Accrued offering costs $ 806 $ 876 Accrued clinical trials 300 376 Accrued compensation 340 400 Accrued other 39 126 Total accrued expenses and other current liabilities $ 1,485 $ 1,778

Debt

Debt	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
DEBT	5. Debt In April 2020, the Company was granted a loan (the “Loan”) in an amount of $ 0.2 million, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted on March 27, 2020. The Loan, which was in the form of a Note dated April 16, 2020, matures on April 16, 2022 and bears interest at a rate of 1.0 % per annum, payable monthly commencing on November 16, 2020 . The Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. Funds from the Loan may only be used for payroll costs, costs used to continue group healthcare benefits, mortgage payments, rent, utilities, and interest on other debt obligations incurred before February 15, 2020. The Company used the entire Loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. In August 2021, the Company repaid the Loan in full. Loan payable at June 30, 2021 and December 31, 2020 consists of the following (in thousands except years and percentage): Year of Interest Outstanding Principal Loan payable 2022 1.00 % $ 174

Convertible Preferred Stock

Convertible Preferred Stock	6 Months Ended
	Jun. 30, 2021
Stockholders Equity Note [Abstract]
Convertible Preferred Stock	6. CONVERTIBLE PREFERRED STOCK Convertible Series A Preferred Stock From January through August 2020, the Company issued 7,048,351 shares of Series A convertible preferred stock (“Series A Preferred Stock”) at $ 3.5833 per share for $ 25.3 million in gross proceeds related to the Series A Preferred Stock agreement from 2018. At June 30, 2021, a total of $ 35.0 million, at $ 3.5833 per share, had been raised by the Company through the Series A preferred financing and the issuance of the Note Series 2018A convertible promissory note that converted into Series A Preferred Stock on May 7, 2018 following the Domestication. The Series A Preferred Stock includes 9,993,727 shares issued and outstanding on June 30, 2021 and December 31, 2020. In connection with the issuance of Series A Preferred Stock in 2018, the Company issued 231,396 warrants to purchase Series A Preferred Stock, accounted for as issuance costs and classified as a liability. In October 2020, the warrants were exercised and converted into Series A Preferred Stock. In August 2020, the Company increased the authorized shares of Series A Preferred Stock, par value $ 0.0001 per share, to 27,564,260 shares. Dividends Dividends at the rate per annum of $ 0.2866 per share shall accrue on the Series A Preferred Stock, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred Stock. Accruing dividends accrue from day to day, whether or not declared, and are cumulative; provided that such accruing dividends are payable only when, as and if declared by the Board of Directors and the Company is under no obligation to pay such accruing dividends. Liquidation The Series A Preferred Stock has a liquidation preference to the holders of common stock. The Series A Preferred Stock has a liquidation preference of $ 3.5833 per share plus any accrued but unpaid dividends. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or a deemed liquidation event, the holders of the shares of Series A Preferred Stock then outstanding are entitled to be paid out of the assets of the Company available for distribution to its stockholders before any payments are made to the holders of common stock by reason of their ownership thereof, an amount per share equal to one times the Series A original issue price, plus any accruing dividends accrued but unpaid thereon, whether or not declared. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or a deemed liquidation event, after payment in full of all Series A liquidation amounts required to be paid to the holders of shares of Series A Preferred Stock, the remaining assets of the Company available for distribution to its stockholders are required to be distributed among the holders of the shares of Series A Preferred Stock and common stock, pro-rata based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted to common stock, provided, that if the aggregate amount which the holders of Series A Preferred Stock are entitled to receive exceeds $ 3.92361 per share (the “Maximum Participation Amount”), each holder of Series A Preferred Stock is entitled to receive upon such liquidation, dissolution or winding up of the Company, the greater of (i) the Maximum Participation Amount and (ii) the amount such holder would have received if all shares of Series A Preferred Stock had been converted into common stock immediately prior to such liquidation, dissolution or winding up of the Company. Voting Rights Each holder of outstanding shares of Series A Preferred Stock is entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of the Series A Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Protective Provisions At any time when at least 131,400 shares of Series A Preferred Stock remain outstanding (subject to appropriate adjustments), the Company shall not take any of the following actions without (1) the vote or written consent of the holders of at least 60% of the then outstanding shares of Series A Preferred Stock separately as a class and (2) prior approval of at least 60 % of the members of the Company’s Board of Directors then in office: (i) liquidate, dissolve or wind-up the business and affairs of the Company, effect any merger or consolidation or any other Deemed Liquidation Event, or consent to any of the foregoing; (ii) amend, alter or repeal any provision of the Company’s certificate of incorporation or bylaws in a manner that adversely affects the powers, preferences or rights of the Series A Preferred Stock; (iii) create, or authorize the creation of, or issue shares of, or obligate itself to issue shares of, any additional class or series of capital stock unless the same ranks junior to the Series A Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends and rights of redemption; (iv) increase or decrease the authorized number of shares of Preferred Stock or of Series A Preferred Stock, or increase or decrease the authorized number of shares of any additional class or series of capital stock of the Company; (v) (a) reclassify, alter or amend any existing security of the Company that is pari passu with the Series A Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to the Series A Preferred Stock in respect of any such right, preference, or privilege or (b) reclassify, alter or amend any existing security of the Company that is junior to the Series A Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to or pari passu with the Series A Preferred Stock in respect of any such right, preference or privilege; (vi) purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of capital stock of the Company other than (a) redemptions of or dividends or distributions on the Series A Preferred Stock as expressly authorized in the Certificate of Incorporation, (b) dividends or other distributions payable on the common stock solely in the form of additional shares of common stock and (c) repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the Company or any subsidiary in connection with the cessation of such employment or service at the lower of the original purchase price or the then current fair market value thereof; (vii) create, or authorize the creation of, or issue, or authorize the issuance of any debt security or permit any subsidiary to take any such action with respect to any debt security, if the aggregate indebtedness of the Company and its subsidiaries for borrowed money following such action would exceed $ 2,000,000 (other than equipment leases or bank lines of credit); (viii) create, or hold capital stock in, any subsidiary that is not wholly owned (either directly or through one or more other subsidiaries) by the Company, or permit any subsidiary to create, or authorize the creation of, or issue or obligate itself to issue, any shares of any class or series of capital stock, or sell, transfer or otherwise dispose of any capital stock of any direct or indirect subsidiary of the Company, or permit any direct or indirect subsidiary to sell, lease, transfer, exclusively license or otherwise dispose (in a single transaction or series of related transactions) of all or substantially all of the assets of such subsidiary; or (ix) increase or decrease the authorized number of directors constituting the Board of Directors. Optional and Mandatory Conversion Rights Each share of Series A Preferred Stock is convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable shares of common stock as is determined by dividing the Series A original issue price by the Series A conversion price in effect at the time of conversion. The Series A conversion price is initially equal to $ 3.5833 . Such initial Series A conversion price, and the rate at which shares of Series A Preferred Stock may be converted into shares of common stock, is subject to adjustment. In connection with the Series A Preferred Stock issuance in August 2020, the Series A conversion price was adjusted to $ 3.2583 . At the time of issuance, no beneficial conversion charge was recorded as the fair value of the Series A Preferred Stock was determined by management to be less than the stated conversion value. When the triggering event that forces conversion where both price and shares are known, the beneficial conversion charge will be recorded. Redemption The Series A Preferred Stock is redeemable upon the occurrence of a deemed liquidation event, which is not solely in control of the Company. Therefore, the Series A Preferred Stock has been classified as temporary equity. Series A Preferred Stock Warrants On May 7, 2018, in connection with the sale and issuance of the Series A Preferred Stock, the Company issued liability-classified warrants to purchase an aggregate of 231,396 shares of Series A Preferred Stock (the “2018 Warrants”), with an exercise price of $ 0.0003 per share of Series A Preferred Stock, subject to adjustment per the terms of the 2018 Warrants. The 2018 Warrants were exercisable immediately on date of issuance and expire five years from issuance, in May 2023 . These warrants were subject to an earlier expiration upon the closing of the Company’s qualifying initial public offering of common stock. In October 2020, the warrants were exercised at the price of $ 0.0003 per share and the warrant liability was settled for its fair value of $ 0.8 million.

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Common Stock	7. COMMON STOCK The Company has 50,700,000 authorized shares of common stock, par value $ 0.0001 per share, of which 3,764,488 shares were issued and outstanding as of June 30, 2021 and December 31, 2021. In October 2020, the Company entered into a common stock purchase agreement with a director of the Company to issue and sell 29,674 shares of its common stock for a total purchase price of $ 0.2 million. In March 2020, the Company entered into a common stock purchase agreement with a director of the Company to issue and sell 182,500 shares of its common stock for a total purchase price of $ 0.2 million.

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	8. STOCK-BASED COMPENSATION 2018 Equity Incentive Plan On May 7, 2018, the Company established and adopted the 2018 Equity Incentive Plan (the “2018 Plan”) providing for the granting of stock awards for employees, directors and consultants to purchase shares of the Company’s common stock. A total of 2,101,478 shares were authorized under the 2018 Plan and 476,840 and 854,320 shares are available for granting of stock awards as of June 30, 2021 and December 31, 2020, respectively. The 2018 Plan provides for the granting of the following types of stock awards: (i) incentive stock options, (ii) non-statutory stock options, (iii) stock appreciation rights, (iv) restricted stock awards, (v) restricted stock unit awards and (vi) other stock awards. Incentive stock options may be granted only to employees of the Company. Stock awards other than incentive stock options may be granted to employees, directors and consultants who are providing continuous service to the Company. The following is a summary of the stock option award activity during the six months ended June 30, 2021: Number Weighted- Weighted- Aggregate Outstanding at December 31, 2020 1,247,158 $ 5.16 9.34 $ 1,486 Granted 305,132 5.36 Exercised — — Cancelled — — Outstanding at June 30, 2021 1,552,290 $ 5.20 9.15 $ 1,486 Exercisable at June 30, 2021 238,172 $ 2.77 8.13 $ 715 Options expected to vest as of June 30, 2021 1,314,118 $ 5.64 9.15 $ 771 Generally, options are granted with an exercise price at, or in excess of, the fair value of common stock at the date of issuance. Options typically vest over a one- to four-year period in equal increments. The original term of all options is 10 years . The weighted-average grant date fair value of options granted during the six months ended June 30, 2021 and 2020 is $ 4.02 and $ 0.96 , respectively. The aggregate intrinsic value is calculated as the difference between the exercise price and the estimated fair value of the Company’s common stock at the end of the reporting period. Stock-Based Compensation Expense For the six months ended June 30, 2021 and 2020, the Company utilized the Black-Scholes option-pricing model for estimating the fair value of the stock options and common stock warrants granted. The following table presents the assumptions and the Company’s methodology for developing each of the assumptions used: June 30, June 30, Volatility 88.78 % 83.3 % Expected life (years) 6.08 6.08 Risk-free interest rate 0.67 % 0.45 %- 1.4 % Dividend rate — % — %  Volatility—The Company estimates the expected volatility of its common stock at the date of grant based on the historical volatility of comparable public companies over the expected term.  Expected life—The expected life is estimated as the contractual term.  Risk-free interest rate—The risk-free rate for periods within the estimated life of the stock award is based on the U.S. Treasury yield curve in effect at the time of grant.  Dividend rate—The assumed dividend yield is based upon the Company’s expectation of not paying dividends in the foreseeable future. Stock-based compensation expense was recorded in the following line items in the condensed statements of operations for the three and six months ended June 30, 2021 and 2020 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Research and development $ 180 $ 17 $ 348 $ 33 General and administrative 212 3 405 5 Total stock-based compensation expense $ 392 $ 20 $ 753 $ 38 No related tax benefits from stock-based compensation expense were recognized for the three and six months ended June 30, 2021 and 2020. As of June 30, 2021, there was $ 4.7 million in unrecognized stock-based compensation cost, which is expected to be recognized over a weighted-average period of 3.0 years .

License Agreements

License Agreements	6 Months Ended
	Jun. 30, 2021
License Agreements [Abstract]
License Agreements	9. LICENSE AGREEMENTS Emory University, Children’s Healthcare of Atlanta, Inc. and UAB Research Foundation In June 2016, the Company entered into an exclusive license agreement with Emory University, Children’s Healthcare of Atlanta, Inc. and UAB, as amended from time to time (the “Emory License Agreement”). The Emory License Agreement was amended in October 2017 and July 2020. Under the Emory License Agreement, the Company obtained an exclusive worldwide license under certain immunotherapy related patents and know-how related to gamma-delta T cells developed by Emory University, Children’s Healthcare of Atlanta, Inc. and UABRF’s affiliate, the University of Alabama at Birmingham, to develop, make, have made, use, sell, import and otherwise commercialize products that are covered by such patents or otherwise incorporate or use the licensed technology. Such exclusive license is subject to certain rights retained by these institutions and also the U.S. government. In consideration of the license granted under the Emory License Agreement, the Company paid Emory University a nominal upfront payment. In addition, the Company is required to pay Emory University development milestones totaling up to an aggregate of $ 1.4 million, low-single-digit to mid-single-digit tiered running royalties on the net sales of the licensed products, including an annual minimum royalty beginning on a specified period after the first sale of a licensed product, and a share of certain payments that the Company may receive from sublicenses. In addition, in the event no milestone payments have been paid in certain years, the Company will be required to pay an annual license maintenance fee. The Emory License Agreement also requires the Company to reimburse Emory University for the cost of the prosecution and maintenance of the licensed patents. Pursuant to the Emory License Agreement, the Company is required to use its best efforts to develop, manufacture and commercialize the licensed product, and is obligated to meet certain specified deadlines in the development of the licensed products. The term of the Emory License Agreement will continue until 15 years after the first commercial sale of the licensed product, or the expiration of the relevant licensed patents, whichever is later. The Company may terminate the Emory License Agreement at will at any time upon prior written notice to Emory University. Emory University has the right to terminate the Emory License Agreement if the Company materially breaches the agreement (including failure to meet diligence obligations) and fails to cure such breach within a specified cure period, if the Company becomes bankrupt or insolvent or decides to cease development and commercialization of the licensed product, or if the Company challenges the validity or enforceability of any licensed patents. Exclusive License Agreement with UABRF In March 2016, the Company entered into an exclusive license agreement with UABRF, as amended from time to time (the “UABRF License Agreement”). The Company amended the UABRF License Agreement in December 2016, January 2017, June 2017 and November 2018. Under the UABRF License Agreement, the Company obtained an exclusive worldwide license under certain immunotherapy-related patents related to the use of gamma-delta T cells, certain CAR-T cells and combination treatments for cellular therapies developed by the University of Alabama at Birmingham and owned by UABRF to develop, make, have made, use, sell, import and otherwise commercialize products that are covered by such patents. Such exclusive license is subject to certain rights retained by UABRF and also the U.S. government. In consideration of the license granted under the UABRF License Agreement, the Company paid UABRF a nominal upfront payment and issued 91,250 shares of common stock to UABRF, which were subject to certain anti-dilution rights. In addition, the Company is required to pay UABRF development milestones totaling up to an aggregate of $ 1.4 million, lump-sum royalties on cumulative net sales totaling up to an aggregate of $ 22.5 million, mid-single-digit running royalties on net sales of the licensed products, low-single-digit running royalties on net sales of the licensed products, and a share of certain non-royalty income that the Company may receive, including from any sublicenses. The UABRF License Agreement also requires the Company to reimburse UABRF for the cost of the prosecution and maintenance of the licensed patents. Pursuant to the UABRF License Agreement, the Company is required to use good faith reasonable commercial efforts to develop, manufacture and commercialize the licensed product. The term of the UABRF License Agreement will continue until the expiration of the licensed patents. The Company may terminate the UABRF License Agreement at will at any time upon prior written notice to UABRF. UABRF has the right to terminate the UABRF License Agreement if the Company materially breaches the agreement and fails to cure such breach within a specified cure period, if the Company fails to diligently undertake development and commercialization activities as set forth in the development and commercialization plan, if the Company underreports its payment obligations or underpays by more than a specified threshold, if the Company challenges the validity or enforceability of any licensed patents, or if the Company becomes bankrupt or insolvent. Antidilution Provision The antidilution provision required the Company to issue additional shares of common stock such that UABRF maintains a 2.5 % ownership interest in the Company until it has raised at least $ 20.0 million through one or more rounds of investment. During the six months ended June 30, 2021 and 2020, the Company did no t issue any additional shares common stock in connection with the antidilution provision. As of June 30, 2021, the Company had a total of 151,382 shares of common stock issued in satisfaction of this antidilution provision. The Company assessed the antidilution right and determined that the right (i) meets the definition of a freestanding financial instrument that was not indexed to the Company’s own stock and (ii) meets the definition of a derivative and did not qualify for equity classification. The initial fair value of the antidilution liability, and the value at June 30, 2020, was determined to be immaterial based on the remote probability of an additional financing and the immaterial value of the total number of shares that could be issued pursuant to the provision. The antidilution provision was settled in August 2020 when the Company raised an additional $ 19.8 million in gross proceeds through the issuance and sale of Series A Preferred Stock for a total of $ 35.0 million in gross proceeds related to the issuance and sale of Series A Preferred Stock.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	10. INCOME TAXES The Company recorded no provision for income taxes for the three and six months ended June 30, 2021 and 2020. Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax bases of assets and liabilities using statutory rates. Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of net operating loss carryforwards and research and development credits. Under the applicable accounting standards, management has considered the Company’s history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of federal and state deferred tax assets. Accordingly, a full valuation allowance has been established against the Company’s otherwise recognizable net deferred tax assets.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	11. NET LOSS PER SHARE Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is the same as basic net loss per share for the periods presented since the effects of potentially dilutive securities are antidilutive given the net loss of the Company. Basic and diluted net loss per share attributable to common stockholders is calculated as follows (in thousands except share and per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Net loss $ ( 3,050 ) $ ( 2,874 ) $ ( 5,413 ) $ ( 4,565 ) Cumulative dividends on convertible preferred stock ( 715 ) ( 304 ) ( 1,421 ) ( 564 ) Net loss attributable to common stockholders $ ( 3,765 ) $ ( 3,178 ) $ ( 6,834 ) $ ( 5,129 ) Net loss per share—basic and diluted $ ( 1.00 ) $ ( 0.92 ) $ ( 1.82 ) $ ( 1.52 ) Weighted-average number of shares used in computing net loss 3,764,488 3,462,182 3,764,488 3,383,774 The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive: For the Six Months Ended June 2021 2020 Convertible preferred stock 9,993,727 4,247,927 Stock options to purchase common stock 1,552,290 392,723 Warrants to purchase preferred stock — 231,396

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and contingencies	12. COMMITMENTS AND CONTINGENCIES Intellectual Property The Company has existing commitments to the licensors of the intellectual property which the Company has licensed. These commitments are based upon certain clinical research, regulatory, financial and sales milestones being achieved. Additionally, the Company is obligated to pay a single-digit royalty on commercial sales on a global basis. The royalty term is the later of 10 years from first commercial sale or expiration of the last-to-expire component of the licensed intellectual property.

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Leases	13. LEASES The Company has historically entered into lease arrangements for its facilities. As of December 31, 2020, the Company had three operating leases with required future minimum payments. In applying the transition guidance under ASC 842, the Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company’s leases generally do not include termination or purchase options. Equipment Leases The Company entered into an agreement with an equipment leasing company in the fall of 2018, which provided up to $ 1.4 million for equipment purchases in the form of sale and leasebacks or direct leases. As of June 30, 2021, the Company had completed the sale and leaseback for four pieces of equipment and is leasing three other items directly from the leasing company. The terms of the leases are three years and afterwards provide for either annual extensions or an outright purchase of the equipment. The equipment leases require two advance rental payments to be held as security deposits. The security deposits held amounted to approximately $ 0.1 million as of June 30, 2021 and December 31, 2020. They are included in other non-current assets on the condensed balance sheets. Operating Leases In December 2020, the Company entered into an operating lease for office space in Birmingham, Alabama, for a 63-month term, ending in March 2026, with an option to extend five years . Throughout the term of the lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. In December 2020, the Company entered into an operating lease for laboratory space in Birmingham, Alabama, for a 63-month term, ending in March 2026, with an option to extend five years . Throughout the term of the lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. The operating leases required security deposits at the inception of the lease. The security deposits amounted to approximately $ 17,000 for the six months ended June 30, 2021. They are included in non-current assets on the balance sheet. The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s finance and operating leases for the three and six months ended June 30, 2021 (in thousands): Three Months Ended Six Months Ended Lease Cost Amortization of finance right-of-use assets $ 138 $ 250 Interest on finance lease liabilities 25 46 Operating lease cost 53 105 Short-term lease cost 134 249 Variable lease cost — — Total lease cost $ 350 $ 650 June 30, 2021 Other Operating Lease Information Cash paid for amounts included in the measurement of lease liability – finance leases $ 340 Cash paid for amounts included in the measurement of lease liability – operating leases $ 52 Weighted-average remaining lease term – finance leases 2.0 Weighted-average remaining lease term – operating leases 4.67 Weighted-average discount rate – finance leases 10.2 % Weighted-average discount rate – operating leases 10.4 % The following table reconciles the undiscounted cash flows to the operating and financing lease liabilities at June 30, 2021 (in thousands): Financing Leases Operating Leases Remainder of 2021 $ 327 $ 105 2022 435 216 2023 253 223 2024 30 230 2025 — 237 Thereafter — 41 Total lease payment 1,045 1,052 Less: interest 96 219 Total lease liability $ 949 $ 833

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	14. SUBSEQUENT EVENTS Subsequent events have been evaluated through the date of filing of the unaudited condensed financial statements. The Company has identified the following subsequent events that require disclosure. Initial Public Offering On August 3, 2021, the Company completed its IPO in which the Company issued and sold 4,000,000 shares of its common stock, at a public offering price of $ 10.00 per share, for aggregate gross proceeds of $ 40.0 million. The Company received approximately $ 32.6 million in net proceeds after deducting underwriting discounts, commissions and estimated offering expenses. In connection with the IPO, all outstanding shares of Series A convertible preferred stock converted into 10,990,065 shares of the Company’s common stock. 2020 Equity Incentive Plan The 2020 Equity Incentive Plan (the “2020 Plan”) was approved by the Board of Directors and the Company’s stockholders and became effective on July 29, 2021. The 2020 Plan provides for the grant of incentive stock options ("ISOs") within the meaning of Section 422 of the U.S. Internal Revenue Code of 1986, as amended, to employees, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants and any affiliates’ employees and consultants. The number of shares initially reserved for issuance under the 2020 Plan was 4,200,000 , which will automatically increase on January 1 of each year for a period of 10 years , beginning on January 1, 2022 and continuing through January 1, 2031, in an amount equal to 5 % of the total number of shares of common stock outstanding on the last day of the immediately preceding year, or a lesser number of shares determined by the Board of Directors no later than the last day of the immediately preceding year. The maximum number of shares of common stock that may be issued on the exercise of ISOs under the 2020 Plan will be 13,000,000 shares. 2020 Employee Stock Purchase Plan The 2020 Employee Stock Purchase Plan (the “2020 ESPP”) was approved by the Company’s Board of Directors and the Company’s stockholders and became effective on July 29, 2021. A total of 200,000 shares of common stock were initially reserved for issuance under this plan, which will automatically increase on January 1 of each year for a period of 10 years , beginning on January 1, 2021 and continuing through January 1, 2031, by the lesser of 1 % of the total number of shares of common stock outstanding on the last day of the immediately preceding year; and 400,000 shares, except before the date of any such increase, the Board of Directors may determine that such increase will be less than the amount set forth above. New York Operating Lease In September 2021, the Company entered into a new operating lease for general office purposes in New York, New York, with a term commencing on September 15, 2021 and continuing through September 2026. The commitment under the new lease is approximately $ 0.3 million annually. Alabama Build-to-Suit Lease In September 2021, the Company entered into a build-to-suit lease agreement with ECBuild to build out the Company's labs in Birmingham Alabama. The agreement has a threshold of $ 4.0 million in total costs incurred. Repayment Loan Payable In A ugust 2021, the Company repaid the PPP loan of $ 0.2 million received in April 2020 in full. Refer to Note 5 “Debt” for further details.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company has prepared the accompanying condensed financial statements in conformity with generally accepted accounting principles in the United States (“US GAAP”).
Unaudited Interim Financial Information	Un audited Interim Financial Information The condensed financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted from these condensed financial statements, as is permitted by such rules and regulations. Accordingly, these condensed financial statements should be read in conjunction with the financial statements and notes thereto for the years ended December 31, 2020 and 2019 included in the Company’s final prospectus that forms part of the Company’s Registration Statement on Form S-1 (File No. 333-249530), filed with the SEC pursuant to Rule 424(b)(4) on July 30, 2021 (the “Prospectus”). The results for any interim period are not necessarily indicative of results for any future period. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included
Use of Estimates	Use of Estimates The preparation of condensed financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed financial statements, and the reported amounts of expenses during the reporting periods presented. Such estimates and assumptions are used for, but are not limited to, the accrual of research and development expenses, deferred tax assets and liabilities and related valuation allowance, fair value of common stock and stock-based compensation, and the useful lives of property and equipment. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Leases	Leases Effective January 1, 2021, the Company adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASU 2016-02” or “ASC 842”), using the modified retrospective method and utilized the effective date as its date of initial application, with prior periods presented in accordance with previous guidance under Accounting Standards Codification ("ASC") ASC 840, Leases . At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease liabilities, as applicable. Operating lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over the expected remaining lease term. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company will adjust the right-of-use assets for straight-line rent expense and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company elected the following practical expedients, which must be elected as a package and applied consistently to all of its leases at the transition date (including those for which the entity is a lessee or a lessor): i) the Company did not reassess whether any expired or existing contracts are or contain leases; ii) the Company did not reassess the lease classification for any expired or existing leases (that is, all existing leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases, and all existing leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases); and iii) the Company did not reassess initial direct costs for any existing leases. For leases that existed prior to the date of initial application of ASC 842 (which were previously classified as operating leases), a lessee may elect to use either the total lease term measured at lease inception under ASC 840 or the remaining lease term as of the date of initial application of ASC 842 in determining the period for which to measure its incremental borrowing rate. In transition to ASC 842, the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates. In accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components, and non-components. The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. Entities may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. On the adoption date, $ 1.7 million was recognized as total lease liabilities and $ 1.8 million was recognized as total right-of-use assets on the Company’s condensed balance sheet.
Deferred Offering Costs	Deferred Offering Costs The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process preferred stock or common stock financings as deferred offering costs until such financings are consummated. The deferred offering costs will be offset against the IPO proceeds during the quarter ending September 30, 2021 as a result of the consummation of the IPO. As of June 30, 2021 and December 31, 2020, the Company had deferred offering costs related to the IPO of $ 3.4 million and $ 2.4 million, respectively.
Recently Issued Accounting Standards Updates	Recently Issued Accounting Standards Updates In December 2019, the Financial Accounting Standards Board ("FASB") issued ASU) No. 2019-12, Simplifying the Accounting for Income Taxes . ASU No. 2019-12 eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. This update is effective for entities other than public business entities, including emerging growth companies that elected to defer compliance with new or revised financial accounting standards until a company that is not an issuer is required to comply with such standards, for annual reporting periods beginning after December 15, 2021, and interim periods within annual periods beginning after December 15, 2022. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on the condensed financial statements.

Property And Equipment, Net (Ta

Property And Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2021
Property Plant And Equipment [Abstract]
Schedule of Components of Property and Equipment, Net	Property and equipment, net consist of the following (in thousands): June 30, December 31, Machinery and equipment $ 443 $ 443 Less accumulated depreciation ( 301 ) ( 257 ) Property and equipment, net $ 142 $ 186

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Payables And Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following (in thousands): June 31, December 31, Accrued offering costs $ 806 $ 876 Accrued clinical trials 300 376 Accrued compensation 340 400 Accrued other 39 126 Total accrued expenses and other current liabilities $ 1,485 $ 1,778

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2021
Loans Payable [Abstract]
Summary of Loan Payable	Loan payable at June 30, 2021 and December 31, 2020 consists of the following (in thousands except years and percentage): Year of Interest Outstanding Principal Loan payable 2022 1.00 % $ 174

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Award Activity	The following is a summary of the stock option award activity during the six months ended June 30, 2021: Number Weighted- Weighted- Aggregate Outstanding at December 31, 2020 1,247,158 $ 5.16 9.34 $ 1,486 Granted 305,132 5.36 Exercised — — Cancelled — — Outstanding at June 30, 2021 1,552,290 $ 5.20 9.15 $ 1,486 Exercisable at June 30, 2021 238,172 $ 2.77 8.13 $ 715 Options expected to vest as of June 30, 2021 1,314,118 $ 5.64 9.15 $ 771
Schedule of Estimating Fair Value of the Stock Options and Common stock Warrants Granted	The following table presents the assumptions and the Company’s methodology for developing each of the assumptions used: June 30, June 30, Volatility 88.78 % 83.3 % Expected life (years) 6.08 6.08 Risk-free interest rate 0.67 % 0.45 %- 1.4 % Dividend rate — % — %
Schedule of Stock-based Compensation Expense	Stock-based compensation expense was recorded in the following line items in the condensed statements of operations for the three and six months ended June 30, 2021 and 2020 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Research and development $ 180 $ 17 $ 348 $ 33 General and administrative 212 3 405 5 Total stock-based compensation expense $ 392 $ 20 $ 753 $ 38

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Share	Basic and diluted net loss per share attributable to common stockholders is calculated as follows (in thousands except share and per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Net loss $ ( 3,050 ) $ ( 2,874 ) $ ( 5,413 ) $ ( 4,565 ) Cumulative dividends on convertible preferred stock ( 715 ) ( 304 ) ( 1,421 ) ( 564 ) Net loss attributable to common stockholders $ ( 3,765 ) $ ( 3,178 ) $ ( 6,834 ) $ ( 5,129 ) Net loss per share—basic and diluted $ ( 1.00 ) $ ( 0.92 ) $ ( 1.82 ) $ ( 1.52 ) Weighted-average number of shares used in computing net loss 3,764,488 3,462,182 3,764,488 3,383,774
Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	The following outstanding potentially dilutive securities have been excluded from the calculation of diluted net loss per share, as their effect is anti-dilutive: For the Six Months Ended June 2021 2020 Convertible preferred stock 9,993,727 4,247,927 Stock options to purchase common stock 1,552,290 392,723 Warrants to purchase preferred stock — 231,396

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Summary of Lease Costs and Other Information to Company's Finance and Operating Liabilities	The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s finance and operating leases for the three and six months ended June 30, 2021 (in thousands): Three Months Ended Six Months Ended Lease Cost Amortization of finance right-of-use assets $ 138 $ 250 Interest on finance lease liabilities 25 46 Operating lease cost 53 105 Short-term lease cost 134 249 Variable lease cost — — Total lease cost $ 350 $ 650 June 30, 2021 Other Operating Lease Information Cash paid for amounts included in the measurement of lease liability – finance leases $ 340 Cash paid for amounts included in the measurement of lease liability – operating leases $ 52 Weighted-average remaining lease term – finance leases 2.0 Weighted-average remaining lease term – operating leases 4.67 Weighted-average discount rate – finance leases 10.2 % Weighted-average discount rate – operating leases 10.4 %
Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Financing Lease Liabilities	The following table reconciles the undiscounted cash flows to the operating and financing lease liabilities at June 30, 2021 (in thousands): Financing Leases Operating Leases Remainder of 2021 $ 327 $ 105 2022 435 216 2023 253 223 2024 30 230 2025 — 237 Thereafter — 41 Total lease payment 1,045 1,052 Less: interest 96 219 Total lease liability $ 949 $ 833

Organization and Nature of Op_2

Organization and Nature of Operations - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Aug. 03, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Organization And Nature Of Operations [Line Items]
Losses from operations		$ 3,050	$ 2,874	$ 5,413	$ 4,565
Accumulated deficit		(23,451)		(23,451)		$ (18,038)
Cash		11,999		11,999		$ 17,994
Proceeds from the issuance of common stock - Class A				0	200
IPO
Organization And Nature Of Operations [Line Items]
Sale of stock, date	Aug. 3, 2021
Sale of shares	4,000,000
Offering price, per share	$ 10
Aggregate net proceeds from offering	$ 32,600
Offering related cost	$ 7,400
Cash		12,000		12,000
Proceeds from the issuance of common stock - Class A				32,600
Series A Financing
Organization And Nature Of Operations [Line Items]
Losses from operations				5,400	$ 4,600
Accumulated deficit		$ (23,500)		$ (23,500)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Jan. 01, 2021	Dec. 31, 2020
Significant Accounting Policies [Line Items]
Lease liabilities	$ 833
Right-of-use assets	762		$ 0
Deferred offering costs	3,362		2,439
IPO
Significant Accounting Policies [Line Items]
Deferred offering costs	$ 3,400		$ 2,400
Accounting Standards Update 2016-02
Significant Accounting Policies [Line Items]
Lease liabilities		$ 1,700
Right-of-use assets		$ 1,800

Property And Equipment, Net - S

Property And Equipment, Net - Schedule of Components of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Machinery and equipment	$ 443	$ 443
Less accumulated depreciation	(301)	(257)
Property and equipment, net	$ 142	$ 186

Property And Equipment, Net - A

Property And Equipment, Net - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Property Plant And Equipment [Abstract]
Depreciation	$ 22,000	$ 22,000	$ 44,000	$ 44,000

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Accrued offering costs	$ 806	$ 876
Accrued clinical trials	300	376
Accrued compensation	340	400
Accrued other	39	126
Total accrued expenses and other current liabilities	$ 1,485	$ 1,778

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended
	Apr. 30, 2020	Jun. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Interest Rate		1.00%	1.00%
Paycheck Protection Program [Member]
Debt Instrument [Line Items]
Loan	$ 200
Loan maturity, date	Apr. 16, 2022
Interest Rate	1.00%
Debt instrument, Payment terms	monthly
Debt instrument, Date of first required payment	Nov. 16, 2020
Prepayment penalties	$ 0

Debt - Summary of Loan Payable

Debt - Summary of Loan Payable (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Loans Payable [Abstract]
Year of Maturity	2022	2022
Interest Rate	1.00%	1.00%
Loan payable	$ 174	$ 174

Convertible Preferred Stock - A

Convertible Preferred Stock - Additional Information (Details) - Series A Preferred Stock - USD ($)	Oct. 31, 2020	Jun. 30, 2021	Aug. 31, 2020	Dec. 31, 2020	May 07, 2018
Class Of Stock [Line Items]
Preferred stock shares issued		9,993,727	7,048,351	9,993,727
Shares issued price per share		$ 3.5833	$ 3.5833
Proceeds from issuance of convertible preferred stock		$ 35,000,000	$ 25,300,000
Preferred stock, per share			$ 0.0001
Preferred stock shares outstanding		9,993,727		9,993,727
Warrants issued to purchase stock		231,396
Preferred stock shares, authorized			27,564,260
Dividends payable, amount, per share		$ 0.2866
Preferred stock, liquidation preference per share		3.5833
Preferred stock, redemption price, per share		$ 3.92361
Aggregate indebtedness		$ 2,000,000,000
Share conversion price per share		$ 3.5833	$ 3.2583
Beneficial conversion charge		$ 0
Series A Preferred Stock Warrants
Class Of Stock [Line Items]
Warrants issued to purchase stock					231,396
Exercise price per unit of warrants	$ 0.0003				$ 0.0003
Warrants and outstanding, term					5 years
Warrants maturity date					May 30, 2023
Payments for settlement of warrants	$ 800,000
Minimum
Class Of Stock [Line Items]
Preferred stock shares outstanding		131,400
Minimum | Series A Stockholders
Class Of Stock [Line Items]
Shareholder consent		60.00%
Minimum | Board Of Directors
Class Of Stock [Line Items]
Shareholder consent		60.00%

Common Stock - Additional Infor

Common Stock - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended
	Oct. 31, 2020	Mar. 31, 2020	Mar. 31, 2020	Jun. 30, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Common stock, shares authorized				50,700,000	50,700,000
Common stock, par value				$ 0.0001	$ 0.0001
Common stock, shares, issued				3,764,488	3,764,488
Common stock, shares, outstanding				3,764,488	3,764,488
Stock issued during period shares new issues, amount			$ 200
Common Stock Purchase Agreement [Member]
Class Of Stock [Line Items]
Stock issued during period shares new issues, amount	$ 200	$ 200
Stock issued during period shares new issues, shares	29,674	182,500

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Common stock, shares authorized	50,700,000		50,700,000		50,700,000
Original term of options			10 years
Weighted average grant-date fair value of options granted			$ 4.02	$ 0.96
Tax benefit from stock based compensation expense	$ 0	$ 0	$ 0	$ 0
Restricted Stock [Member]
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Share-based payment arrangement, unrecognized stock based compensation cost	$ 4,700,000		$ 4,700,000
Performance Based Award [Member]
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Weighted-average period over which cost not yet recognized is expected to be recognized			3 years
Minimum
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Vesting period			1 year
Maximum
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Vesting period			4 years
2018 Equity Incentive Plan
Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]
Common stock, shares authorized	2,101,478		2,101,478
Stock awards, granted			476,840		854,320

Stock-based Compensation - Summ

Stock-based Compensation - Summary of Stock Option Award Activities (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options outstanding, beginning balance	1,247,158
Options granted	305,132
Options exercised	0
Options cancelled	0
Options outstanding, ending balance	1,552,290	1,247,158
Options exercisable	238,172
Options vested or expected to vest	1,314,118
Options outstanding, weighted average exercise price, beginning balance	$ 5.16
Options granted, weighted average exercise price	5.36
Options exercised, weighted average exercise price	0
Options cancelled, weighted average exercise price	0
Options outstanding, weighted average exercise price, ending balance	5.20	$ 5.16
Options exercisable, weighted average exercise price	2.77
Options vested or expected to vest, weighted average exercise price	$ 5.64
Options outstanding, weighted average remaining contractual term	9 years 1 month 24 days	9 years 4 months 2 days
Options exercisable, weighted average remaining contractual term	8 years 1 month 17 days
Options vested or expected to vest, weighted average remaining contractual term	9 years 1 month 24 days
Options outstanding, aggregate intrinsic value	$ 1,486	$ 1,486
Options exercisable, aggregate intrinsic value	715
Options vested or expected to vest, aggregate intrinsic value	$ 771

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Estimating Fair Value of the Stock Options and Common stock Warrants Granted (Details)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Employee Service Share Based Compensation Aggregate Disclosures [Abstract]
Volatility	88.78%	83.30%
Expected life (years)	6 years 29 days	6 years 29 days
Risk-free interest rate	0.67%
Risk-free interest rate minimum		0.45%
Risk-free interest rate maximum		1.40%
Dividend rate	0.00%	0.00%

Stock-based Compensation - Sc_2

Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 392	$ 361	$ 20	$ 18	$ 753	$ 38
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	180		17		348	33
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 212		$ 3		$ 405	$ 5

License Agreements - Additional

License Agreements - Additional Information (Details) - USD ($)	1 Months Ended	6 Months Ended
	Aug. 31, 2020	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Common stock, shares, issued		3,764,488	3,764,488
UABRF [Member] | Antidilution Provision [Member]
Common stock, shares, issued		151,382
Equity Method Investment, Ownership Percentage		2.50%
Raise of investment		$ 20,000,000
Common stock additional shares issued		0		0
UABRF [Member] | Antidilution Provision [Member] | Series A Preferred Stock [Member]
Raise of investment	$ 19,800,000
Preferred stock shares issued	$ 35,000,000
Emory License Agreement [Member] | UABRF [Member]
Aggregate pay for development milestones total		$ 1,400,000
License agreement description		The term of the Emory License Agreement will continue until 15 years after the first commercial sale of the licensed product, or the expiration of the relevant licensed patents, whichever is later.
Exclusive License Agreement [Member] | UABRF [Member]
Common stock, shares, issued		91,250
Royalties on cumulative net sales		$ 22,500,000
Exclusive License Agreement [Member] | UABRF [Member] | Maximum
Milestone payment		$ 1,400,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0	$ 0	$ 0	$ 0

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Earnings Per Share [Abstract]
Net loss	$ (3,050)	$ (2,363)	$ (2,874)	$ (1,691)	$ (5,413)	$ (4,565)
Cumulative dividends on convertible preferred stock	(715)		(304)		(1,421)	(564)
Net loss attributable to common stockholders	$ (3,765)		$ (3,178)		$ (6,834)	$ (5,129)
Net loss per share attributable to common stockholders – basic and diluted	$ (1)		$ (0.92)		$ (1.82)	$ (1.52)
Weighted-average number of shares used in computing net loss per common share, basic and diluted	3,764,488		3,462,182		3,764,488	3,383,774

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from calculation of diluted net loss per share	9,993,727	4,247,927
Stock Options To Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from calculation of diluted net loss per share	1,552,290	392,723
Warrants to Purchase Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from calculation of diluted net loss per share	0	231,396

Commitments and Contingencies (

Commitments and Contingencies (Additional Information) (Details)	6 Months Ended
	Jun. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Royalty term	10 years

Leases - Additional Information

Leases - Additional Information (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Birmingham, Alabama
Loss Contingencies [Line Items]
Security deposit	$ 17,000
Office Building | Birmingham, Alabama
Loss Contingencies [Line Items]
Operating lease, term of contract		63 months
Operating lease, option to extend		option to extend five years
Operating lease, existence of option to extend		true
Laboratory | Birmingham, Alabama
Loss Contingencies [Line Items]
Operating lease, term of contract		63 months
Operating lease, option to extend		option to extend five years
Operating lease, existence of option to extend		true
Equipment
Loss Contingencies [Line Items]
Leaseback transaction, description	Company had completed the sale and leaseback for four pieces of equipment and is leasing three other items directly from the leasing company. The terms of the leases are three years and afterwards provide for either annual extensions or an outright purchase of the equipment.
Security deposit	$ 100,000	$ 100,000
Equipment | Maximum
Loss Contingencies [Line Items]
Amount held for equipment purchases	$ 1,400,000

Leases - Summary of Lease Costs

Leases - Summary of Lease Costs and Other Information to Company's Finance and Operating Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020
Lease Cost
Amortization of financing lease right-of-use assets	$ 138	$ 250	$ 0
Interest on finance lease liabilities	25	46
Operating lease cost	53	105
Short-term lease cost	134	249
Variable lease cost	0	0
Total lease cost	350	650
Cash paid for amounts included in the measurement of lease liability – finance leases	340	340
Cash paid for amounts included in the measurement of lease liability – operating leases	$ 52	$ 52
Weighted-average remaining lease term – finance leases	2 years	2 years
Weighted-average remaining lease term – operating leases	4 years 8 months 1 day	4 years 8 months 1 day
Weighted-average discount rate – finance leases	10.20%	10.20%
Weighted-average discount rate – operating leases	10.40%	10.40%

Leases - Schedule of Reconcilia

Leases - Schedule of Reconciliation of Undiscounted Cash Flows to Operating and Finance Lease Liabilities (Details) $ in Thousands	Jun. 30, 2021USD ($)
Leases [Abstract]
Remainder of 2021	$ 327
2022	435
2023	253
2024	30
2025	0
Thereafter	0
Total lease payment	1,045
Less: interest	96
Total lease liability	949
Remainder of 2021	105
2022	216
2023	223
2024	230
2025	237
Thereafter	41
Total lease payment	1,052
Less: interest	219
Total lease liability	$ 833

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Aug. 03, 2021	Sep. 30, 2021	Aug. 31, 2021	Jun. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Common stock, shares, issued				3,764,488	3,764,488	3,764,488
Operating lease cost				$ 53	$ 105
Subsequent Event [Member] | New York Operating Lease
Subsequent Event [Line Items]
Operating lease cost		$ 300
Subsequent Event [Member] | Alabama Build-to-Suit Lease
Subsequent Event [Line Items]
Operating lease cost		$ 4,000
Subsequent Event [Member] | Paycheck Protection Program [Member]
Subsequent Event [Line Items]
Repayment of loan payable			$ 200
Subsequent Event [Member] | 2020 Equity Incentive Plan [Member]
Subsequent Event [Line Items]
Common stock reserved for future issuance			4,200,000
Shares reserved of issuance under the plan increase duration			10 years
Percentage of number of shares of common stock outstanding			5.00%
Maximum number of shares of common stock issuable			13,000,000
Subsequent Event [Member] | 2020 Employee Stock Purchase Plan [Member]
Subsequent Event [Line Items]
Common stock reserved for future issuance			200,000
Shares reserved of issuance under the plan increase duration			10 years
Percentage of number of shares of common stock outstanding			1.00%
Maximum number of shares of common stock issuable			400,000
Subsequent Event [Member] | IPO
Subsequent Event [Line Items]
Common stock, shares, issued	4,000,000
Shares issued price per share	$ 10
Gross proceeds	$ 40,000
Proceeds from issuance initial public offering net proceeds	$ 32,600
Convertible preferred stock shares issued upon conversion	10,990,065